(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the Euronext session.
The three biggest winners today are VALNEVA, ESTORIL SOL N, and VIVORYON.
| Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|
| VALNEVA (VLA.PA) | 4.82 | 14.49% | 2023-05-04 11:05:18 |
| ESTORIL SOL N (ESON.LS) | 8.00 | 10.34% | 2023-05-04 11:18:50 |
| VIVORYON (VVY.AS) | 16.04 | 6.93% | 2023-05-04 11:05:31 |
| NAVAMEDIC (NAVA.OL) | 38.50 | 6.65% | 2023-05-04 11:31:36 |
| OTELLO CORPORATION (OTEC.OL) | 7.98 | 6.12% | 2023-05-04 11:32:33 |
| NEPI ROCKCASTLE (NRP.AS) | 5.50 | 5.77% | 2023-05-04 11:03:46 |
| AUGROS COSMETICS (AUGR.PA) | 7.55 | 5.59% | 2023-05-04 11:37:08 |
| PEXIP HOLDING (PEXIP.OL) | 20.06 | 5.58% | 2023-05-04 11:32:45 |
| AMG (AMG.AS) | 36.16 | 5.12% | 2023-05-04 11:00:34 |
| ARCADIS (ARCAD.AS) | 39.00 | 4.9% | 2023-05-04 11:00:38 |
The three biggest losers today are WALLENIUS WILHELMS, MAREL, and KAHOOT!.
| Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|
| WALLENIUS WILHELMS (WAWI.OL) | 64.70 | -16.25% | 2023-05-04 08:34:45 |
| MAREL (MAREL.AS) | 3.34 | -16.08% | 2023-05-04 11:03:30 |
| KAHOOT! (KAHOT.OL) | 22.33 | -14.38% | 2023-05-04 11:30:48 |
| MEDINCELL (MEDCL.PA) | 8.32 | -10.73% | 2023-05-04 11:00:14 |
| CASINO GUICHARD (CO.PA) | 7.49 | -10.4% | 2023-05-04 11:46:06 |
| AIRTHINGS (AIRX.OL) | 2.23 | -8.44% | 2023-05-04 11:20:23 |
| GENSIGHT BIOLOGICS (SIGHT.PA) | 0.50 | -8.29% | 2023-05-04 11:50:32 |
| TIETOEVRY (TIETO.OL) | 320.80 | -8.19% | 2023-05-04 11:34:45 |
| BALYO (BALYO.PA) | 0.54 | -8.19% | 2023-05-04 11:45:08 |
| NANOBIOTIX (NANO.PA) | 1.67 | -7.73% | 2023-05-04 11:00:48 |
Winners today
1. VALNEVA (VLA.PA)
14.49% Price Change
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.
CAC 40 ended the session with VALNEVA rising 14.49% to €4.82 on Thursday while CAC 40 dropped 0.85% to €7,340.77.
Earnings Per Share
As for profitability, VALNEVA has a trailing twelve months EPS of €-1.16.
Volume
Today’s last reported volume for VALNEVA is 870926 which is 143.16% above its average volume of 358165.
Volatility
VALNEVA’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.22%, a negative 0.94%, and a positive 1.91%.
VALNEVA’s highest amplitude of average volatility was 1.68% (last week), 1.95% (last month), and 1.91% (last quarter).
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, VALNEVA’s stock is considered to be overbought (>=80).
More news about VALNEVA.
2. ESTORIL SOL N (ESON.LS)
10.34% Price Change
Estoril Sol, SGPS, S.A., together with its subsidiaries, engages in the gaming activities and real estate businesses. It owns gaming casinos, including casino do Estoril, Casino Lisboa, and Casino da Póvoa. The company is also involved in the online casino games and gambling business, as well as online sports betting activities. In addition, it owns a plot of land in Monte Estoril. Further, the company engages in tourism business. The company was incorporated in 1958 and is headquartered in Estoril, Portugal. Estoril Sol, SGPS, S.A. is a subsidiary of Finansol – Sociedade de Controlo, SGPS, S.A.
PSI ended the session with ESTORIL SOL N rising 10.34% to €8.00 on Thursday, following the last session’s upward trend. PSI jumped 0.36% to €6,090.34, after three successive sessions in a row of losses, on what was a somewhat bullish trend exchanging session today.
Earnings Per Share
As for profitability, ESTORIL SOL N has a trailing twelve months EPS of €2.86.
PE Ratio
ESTORIL SOL N has a trailing twelve months price to earnings ratio of 2.8. Meaning, the purchaser of the share is investing €2.8 for every euro of annual earnings.
Volatility
ESTORIL SOL N’s last week, last month’s, and last quarter’s current intraday variation average was 3.57%, 3.64%, and 4.21%.
ESTORIL SOL N’s highest amplitude of average volatility was 3.57% (last week), 3.64% (last month), and 4.21% (last quarter).
More news about ESTORIL SOL N.
3. VIVORYON (VVY.AS)
6.93% Price Change
Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease. In addition, the company is developing a monoclonal antibody PBD-C06 is for N3pE-Abeta. Vivoryon Therapeutics N.V. has a collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology, as well as a strategic regional licensing partnership with Simcere Pharmaceutical Group Ltd. to develop and commercialize medicines targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to treat Alzheimer's disease. Vivoryon Therapeutics N.V. was founded in 1997 and is headquartered in Halle, Germany.
AEX-Index ended the session with VIVORYON rising 6.93% to €16.04 on Thursday while AEX-Index slid 0.41% to €741.22.
Earnings Per Share
As for profitability, VIVORYON has a trailing twelve months EPS of €-0.72.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, VIVORYON’s stock is considered to be oversold (<=20).
More news about VIVORYON.
4. NAVAMEDIC (NAVA.OL)
6.65% Price Change
Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Northern Europe. The company's product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic acidemia/propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases and renal diseases, fat metabolism, malnutrition, and ketogenic diet. In addition, the company provides consumer health products consisting of non-prescription drugs and health care products for pain relief, cough and cold, gastro, women's health, and others primarily through pharmacies and drugstores; specialty pharmaceutical products in various therapeutic areas comprising dermatology, wound care, women's health, urology, and obesity; and branded generics, including cardiology products and antibiotics. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was incorporated in 2002 and is headquartered in Oslo, Norway.
Oslo Børs Benchmark Index_GI ended the session with NAVAMEDIC rising 6.65% to €38.50 on Thursday, following the last session’s upward trend. Oslo Børs Benchmark Index_GI dropped 1.14% to €1,189.72, after two successive sessions in a row of losses, on what was an all-around negative trend exchanging session today.
Earnings Per Share
As for profitability, NAVAMEDIC has a trailing twelve months EPS of kr0.45.
PE Ratio
NAVAMEDIC has a trailing twelve months price to earnings ratio of 85.56. Meaning, the purchaser of the share is investing kr85.56 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.31%.
Yearly Top and Bottom Value
NAVAMEDIC’s stock is valued at kr38.50 at 22:40 EST, way under its 52-week high of kr43.60 and way higher than its 52-week low of kr25.00.
Revenue Growth
Year-on-year quarterly revenue growth grew by 28.6%, now sitting on 382.14M for the twelve trailing months.
Sales Growth
NAVAMEDIC’s sales growth is 72.2% for the current quarter and 9.6% for the next.
More news about NAVAMEDIC.
5. OTELLO CORPORATION (OTEC.OL)
6.12% Price Change
Otello Corporation ASA provides cloud-based network solutions for mobile operators. It offers RocketColony, which enables mobile operators to optimize their network performance and quality. The company was formerly known as Opera Software ASA and changed its name to Otello Corporation ASA in January 2018. Otello Corporation ASA was founded in 1995 and is based in Oslo, Norway.
Oslo Børs Benchmark Index_GI ended the session with OTELLO CORPORATION rising 6.12% to €7.98 on Thursday, following the last session’s downward trend. Oslo Børs Benchmark Index_GI dropped 1.14% to €1,189.72, after two sequential sessions in a row of losses, on what was an all-around bearish trend trading session today.
Earnings Per Share
As for profitability, OTELLO CORPORATION has a trailing twelve months EPS of kr1.92.
PE Ratio
OTELLO CORPORATION has a trailing twelve months price to earnings ratio of 4.16. Meaning, the purchaser of the share is investing kr4.16 for every norwegian krone of annual earnings.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Aug 9, 2022, the estimated forward annual dividend rate is 21 and the estimated forward annual dividend yield is 263.82%.
Moving Average
OTELLO CORPORATION’s value is higher than its 50-day moving average of kr7.82 and way below its 200-day moving average of kr9.86.
Yearly Top and Bottom Value
OTELLO CORPORATION’s stock is valued at kr7.98 at 22:40 EST, way below its 52-week high of kr32.00 and higher than its 52-week low of kr7.29.
Volume
Today’s last reported volume for OTELLO CORPORATION is 34892 which is 165.76% above its average volume of 13129.
More news about OTELLO CORPORATION.
6. NEPI ROCKCASTLE (NRP.AS)
5.77% Price Change
NEPI Rockcastle is the premier owner and operator of shopping centres in Central and Eastern Europe (CEE), with presence in nine countries and an investment portfolio of €5.8 billion as at 31 December 2021. The Group benefits from a highly-skilled internal management team which combines asset management, development, investment, leasing and financial expertise. Geographically diverse management skills allow NEPI Rockcastle to pursue CEE property opportunities efficiently, benefiting from a strategic advantage in the acquisition, development and management of properties. NEPI Rockcastle owns and operates 52 retail properties (excluding joint venture) which attracted 244 million visits in 2021 (325 million visits in 2019). With group-level management of tenant relationships and a focus on cross-country collaboration, the Group is the leading strategic partner for major retailers targeting CEE countries. The Group's financial strategy includes maintaining a profile of adequate liquidity, conservative gearing, and a diverse debt structure, which combines secured and unsecured bank debt with unsecured bonds listed on the Irish Stock Exchange. NEPI Rockcastle is investment-grade rated by Standard & Poor's (BBB, stable outlook) and Fitch (BBB, positive outlook). NEPI Rockcastle's shares are listed on the Johannesburg Stock Exchange (“JSE”), Euronext Amsterdam (“Euronext”) and A2X. The Group voluntarily distributes at least 90% of its distributable earnings on a semi-annual basis.
AEX-Index ended the session with NEPI ROCKCASTLE jumping 5.77% to €5.50 on Thursday, after five sequential sessions in a row of losses. AEX-Index slid 0.41% to €741.22, after two consecutive sessions in a row of losses, on what was a somewhat negative trend exchanging session today.
Earnings Per Share
As for profitability, NEPI ROCKCASTLE has a trailing twelve months EPS of €0.66.
PE Ratio
NEPI ROCKCASTLE has a trailing twelve months price to earnings ratio of 8.33. Meaning, the purchaser of the share is investing €8.33 for every euro of annual earnings.
Volume
Today’s last reported volume for NEPI ROCKCASTLE is 150 which is 48.8% below its average volume of 293.
Volatility
NEPI ROCKCASTLE’s last week, last month’s, and last quarter’s current intraday variation average was a negative 7.69%, a negative 1.16%, and a positive 5.48%.
NEPI ROCKCASTLE’s highest amplitude of average volatility was 7.69% (last week), 5.42% (last month), and 5.48% (last quarter).
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, NEPI ROCKCASTLE’s stock is considered to be overbought (>=80).
More news about NEPI ROCKCASTLE.
7. AUGROS COSMETICS (AUGR.PA)
5.59% Price Change
Augros Cosmetic Packaging SA provides customized packaging solutions in France. The company offers decoration solutions for glass, plastic, and aluminum packaging materials. It serves the perfume, cosmetic, and spirit industries. The company is based in Alencon, France. Augros Cosmetic Packaging SA operates as a subsidiary of Famille Bourgine.
CAC 40 ended the session with AUGROS COSMETICS rising 5.59% to €7.55 on Thursday while CAC 40 fell 0.85% to €7,340.77.
Earnings Per Share
As for profitability, AUGROS COSMETICS has a trailing twelve months EPS of €0.25.
PE Ratio
AUGROS COSMETICS has a trailing twelve months price to earnings ratio of 30.2. Meaning, the purchaser of the share is investing €30.2 for every euro of annual earnings.
Volume
Today’s last reported volume for AUGROS COSMETICS is 47 which is 88.27% below its average volume of 401.
More news about AUGROS COSMETICS.
8. PEXIP HOLDING (PEXIP.OL)
5.58% Price Change
Pexip Holding ASA, a video technology company, provides end-to-end video conferencing platform and digital infrastructure worldwide. The company offers self-hosted software application and as-a-service deployment options for enterprise video conferencing, built on its proprietary Infinity technology. Its interoperability solutions are integrated into Microsoft Teams, Skype for Business, and Google Hangouts. The company serves government, healthcare, education, finance, legal, judicial, and retail industries. Pexip Holding ASA was founded in 2011 and is headquartered in Oslo, Norway.
Oslo Børs Benchmark Index_GI ended the session with PEXIP HOLDING rising 5.58% to €20.06 on Thursday, following the last session’s downward trend. Oslo Børs Benchmark Index_GI slid 1.14% to €1,189.72, after two consecutive sessions in a row of losses, on what was an all-around bearish trend trading session today.
Earnings Per Share
As for profitability, PEXIP HOLDING has a trailing twelve months EPS of kr-2.49.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -14.97%.
Moving Average
PEXIP HOLDING’s value is way higher than its 50-day moving average of kr14.64 and way above its 200-day moving average of kr12.54.
Earnings Before Interest, Taxes, Depreciation, and Amortization
PEXIP HOLDING’s EBITDA is -61.3.
Revenue Growth
Year-on-year quarterly revenue growth declined by 2.1%, now sitting on 867.06M for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 100% and 100%, respectively.
More news about PEXIP HOLDING.
9. AMG (AMG.AS)
5.12% Price Change
AMG Advanced Metallurgical Group N.V. produces and sells engineered specialty metals and mineral products. It also provides vacuum furnace and hybrid energy storage systems to the transportation, infrastructure, energy, and specialty metals and chemicals markets. The company operates through three segments, AMG Clean Energy Materials, AMG Critical Minerals and AMG Critical Materials Technologies. The AMG Clean Energy Materials segment operates and produces materials for infrastructure and energy storage solutions, as well as offers vanadium, lithium, and tantalum value chain elements. The AMG Critical Minerals segment operates and processes graphite, antimony, and silicon related metals. The AMG Critical Materials Technologies engages in vacuum furnace technology related activities. It primarily operates in the United States, China, Germany, Brazil, Italy, the United Kingdom, France, Canada, the Czech Republic, Japan, Austria, Thailand, India, Belgium, Mexico, South Korea, Poland, Turkey, Australia, Sweden, Spain, Netherlands, Taiwan, Switzerland, Argentina, Singapore, Russia, Kazakhstan, Mozambique, and internationally. The company was incorporated in 2006 and is headquartered in Amsterdam, the Netherlands.
AEX-Index ended the session with AMG jumping 5.12% to €36.16 on Thursday while AEX-Index dropped 0.41% to €741.22.
Earnings Per Share
As for profitability, AMG has a trailing twelve months EPS of €5.4.
PE Ratio
AMG has a trailing twelve months price to earnings ratio of 6.7. Meaning, the purchaser of the share is investing €6.7 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 46.99%.
More news about AMG.
10. ARCADIS (ARCAD.AS)
4.9% Price Change
Arcadis NV operates as a design and consultancy firm for natural and built assets worldwide. The company operates through four segments: Europe & Middle East, The Americas, Asia Pacific, and CallisonRTKL. It offers architectural based design consultancy services; and asset management services, such as asset management strategy and planning, asset management decision making and operational optimization, life cycle planning and asset management systems, asset information/condition assessment, risk and review, organization and people, and asset management/O&M. The company also provides business advisory services, including asset strategy and performance, business transformation and resiliency, investment and finance, operations and maintenance, and technology and information; cost and commercial management services; and design and engineering solutions for highways, railways, bridges, tunnels, power utilities, water utilities, ports and waterways, geotechnics, architecture, and structures, as well as building mechanical, electrical, and plumbing. In addition, it offers digital environmental health safety and sustainability, environmental restoration, and project management solutions. Further, the company provides mobility solutions for connected highways, intelligent rail and transit, integrated airports, and new mobility; places solutions; resilience solutions, including climate adaption, energy transition, enviro socio permitting, environmental restoration, sustainable advisory, sustainable operations, and water optimization; and water supply and treatment, distribution, resource management, and industrial water and wastewater services. It serves industrial manufacturing, technology, property and investment, contractors, and energy and resources sectors. The company was formerly known as Heidemij NV and changed its name to Arcadis N.V. in October 1997. Arcadis NV was founded in 1888 and is headquartered in Amsterdam, the Netherlands.
AEX-Index ended the session with ARCADIS rising 4.9% to €39.00 on Thursday, following the last session’s upward trend. AEX-Index dropped 0.41% to €741.22, after two successive sessions in a row of losses, on what was a somewhat bearish trend trading session today.
Earnings Per Share
As for profitability, ARCADIS has a trailing twelve months EPS of €1.52.
PE Ratio
ARCADIS has a trailing twelve months price to earnings ratio of 25.66. Meaning, the purchaser of the share is investing €25.66 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.1%.
Volume
Today’s last reported volume for ARCADIS is 133677 which is 12.06% above its average volume of 119284.
Volatility
ARCADIS’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.15%, a negative 0.16%, and a positive 1.17%.
ARCADIS’s highest amplitude of average volatility was 0.72% (last week), 0.94% (last month), and 1.17% (last quarter).
More news about ARCADIS.
Losers Today
1. WALLENIUS WILHELMS (WAWI.OL)
-16.25% Price Change
Wallenius Wilhelmsen ASA, together with its subsidiaries, transports and handle cars, tractors, trains, and windmills. It operates through three segments: Shipping Services, Logistics Services, and Government Services. The company provides liner services through a fleet of modern and versatile RoRo vessels, which carry a mix of products, such as auto, construction, mining, agriculture machinery, and breakbulk products. In addition, it offers inland transportation services, as well as operates vehicle and equipment processing centres and inland distribution networks. The company serves agriculture, automotive, aviation, boats and yachts, breakbulk, commercial vehicles, construction, machinery and machine tools, mining, oil and gas, power and energy, and rail industries. It operates approximately 125 vessels servicing 15 trade routes. The company was founded in 1861 and is based in Lysaker, Norway.
Oslo Børs Benchmark Index_GI ended the session with WALLENIUS WILHELMS falling 16.25% to €64.70 on Thursday while Oslo Børs Benchmark Index_GI fell 1.14% to €1,189.72.
Earnings Per Share
As for profitability, WALLENIUS WILHELMS has a trailing twelve months EPS of kr16.01.
PE Ratio
WALLENIUS WILHELMS has a trailing twelve months price to earnings ratio of 4.04. Meaning, the purchaser of the share is investing kr4.04 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.73%.
Volume
Today’s last reported volume for WALLENIUS WILHELMS is 1085910 which is 274.63% above its average volume of 289857.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 37.7% and 109.2%, respectively.
More news about WALLENIUS WILHELMS.
2. MAREL (MAREL.AS)
-16.08% Price Change
Marel hf. develops, distributes, and sells solutions, software, and services to food processing industries in Europe, the Middle East, Africa, the Americas, Asia, and Oceania. The company's Poultry Processing segment offers integrated systems, software, and services for processing broilers, turkeys, and ducks. Its Meat Processing segment supplies primary, secondary, and further processing equipment, systems, software, and services of pork, beef, veal, and sheep. The company's Fish Processing segment offers equipment, systems, software, and services for farmed and wild salmon and whitefish processing. Its Plant, pet and feed segment provides solutions and services to the pet food, plant-based protein, and aqua feed markets. Marel hf. was founded in 1977 and is based in Garðabær, Iceland.
AEX-Index ended the session with MAREL falling 16.08% to €3.34 on Thursday, following the last session’s upward trend. AEX-Index fell 0.41% to €741.22, after two consecutive sessions in a row of losses, on what was a somewhat down trend trading session today.
Earnings Per Share
As for profitability, MAREL has a trailing twelve months EPS of €0.08.
PE Ratio
MAREL has a trailing twelve months price to earnings ratio of 41.75. Meaning, the purchaser of the share is investing €41.75 for every euro of annual earnings.
Volume
Today’s last reported volume for MAREL is 80439 which is 125.94% above its average volume of 35601.
More news about MAREL.
3. KAHOOT! (KAHOT.OL)
-14.38% Price Change
Kahoot! ASA operates a learning and engagement platform in the United States, Canada, Europe, the Asia Pacific, the Latin America and the Caribbean, Africa, the Middle East, and India. The company's platforms help to create, share, and host learning sessions. It offers Kahoot! Learning platform for learning and engagement services; employee engagement and learning platforms, such as Actimo and Motimate; Drops, a language learning app for visuals and play; Kahoot! DragonBox app for math learning; and Kahoot! Poio Read app, which empowers children to learn to read through play. The company also provides Kahoot! Academy, a global community and knowledge platform for all creators, learners and learning providers; Kahoot! 360 Spirit; Kahoot! Marketplace, an emerging global digital marketplace for learning resources on Kahoot; Kahoot! EDU support program, a site license for schools and districts; and Whiteboard.fi, an online whiteboard that provides learning tools for educators, teachers, and classrooms. In addition, it offers Kahoot! Zoom App platform for engagement and learning to virtual meetings and events; and Clever, a single sign-on digital learning platform for teachers and students. Kahoot! ASA was incorporated in 2011 and is headquartered in Oslo, Norway.
Oslo Børs Benchmark Index_GI ended the session with KAHOOT! dropping 14.38% to €22.33 on Thursday, after two successive sessions in a row of losses. Oslo Børs Benchmark Index_GI dropped 1.14% to €1,189.72, after two successive sessions in a row of losses, on what was an all-around bearish trend trading session today.
Earnings Per Share
As for profitability, KAHOOT! has a trailing twelve months EPS of kr0.05.
PE Ratio
KAHOOT! has a trailing twelve months price to earnings ratio of 446.6. Meaning, the purchaser of the share is investing kr446.6 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 0.38%.
More news about KAHOOT!.
4. MEDINCELL (MEDCL.PA)
-10.73% Price Change
MedinCell S.A. develops various therapeutic solutions in France. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. The company's products in development include mdc-IRM, a risperidone extended-release injectable suspension completed Phase III trial for use in the treatment of schizophrenia; mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain & inflammation; and mdc-TJK, a subcutaneous injection in Phase III trials for use in the treatment of schizophrenia. Its product candidates in preclinical trials, such as mdc-ANG, an antipsychotic product for use in the treatment of schizophrenia; mdc-TTG for Covid-19 and its variants; mdc-GRT for use in organ transplant; mdc-WWM for contraception; mdc-STM for use in malaria; mdc-KPT for use in acute pain for pets; and mdc-IRM for use in neuroscience. The company was incorporated in 2003 and is based in Jacou, France.
CAC 40 ended the session with MEDINCELL sliding 10.73% to €8.32 on Thursday while CAC 40 slid 0.85% to €7,340.77.
Earnings Per Share
As for profitability, MEDINCELL has a trailing twelve months EPS of €-1.2.
Volatility
MEDINCELL’s last week, last month’s, and last quarter’s current intraday variation average was a positive 2.66%, a negative 0.19%, and a positive 2.72%.
MEDINCELL’s highest amplitude of average volatility was 9.96% (last week), 3.24% (last month), and 2.72% (last quarter).
Volume
Today’s last reported volume for MEDINCELL is 118035 which is 108.1% above its average volume of 56720.
Revenue Growth
Year-on-year quarterly revenue growth grew by 276.2%, now sitting on 8.52M for the twelve trailing months.
More news about MEDINCELL.
5. CASINO GUICHARD (CO.PA)
-10.4% Price Change
Casino, Guichard-Perrachon S.A. operates as a food retailer in France, Latin America, and internationally. The company operates hypermarkets, supermarkets, shopping malls, and e-commerce sites, as well as convenience, discount, and cash and carry stores. It also involved in banking, digital marketing, service station, franchise, real estate asset management, property development and trading, rental, banking, and energy-related activities. It operates through stores. The company was founded in 1898 and is based in Saint-Étienne, France.
CAC 40 ended the session with CASINO GUICHARD sliding 10.4% to €7.49 on Thursday while CAC 40 slid 0.85% to €7,340.77.
Earnings Per Share
As for profitability, CASINO GUICHARD has a trailing twelve months EPS of €-3.81.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -5.53%.
More news about CASINO GUICHARD.
6. AIRTHINGS (AIRX.OL)
-8.44% Price Change
Airthings ASA, a hardware-enabled software company, develop products and systems for monitoring indoor air quality, radon, and energy efficiency worldwide. It operates through Consumer, Business, and Professional segments. The Consumer segments sells air quality sensors to private customers through retail and e-commerce. Its Business segment provides air quality solutions to schools, office building, and other commercial buildings. The Professional segment sells measurement solutions, which enables inspectors and certified radon professionals to measure, analyze, and report on buildings; and offers rental of products and calibration services. In addition, it offers digital radon detectors as well as smart indoor air quality monitors and solutions. The company provides its products under the View Plus, Wave Plus, Wave Radon, Wave Mini, House Kit, Hub, Corentium Home, Plus, and Pro brands. Airthings ASA was incorporated in 2008 and is headquartered in Oslo, Norway.
Oslo Børs Benchmark Index_GI ended the session with AIRTHINGS dropping 8.44% to €2.23 on Thursday, after four sequential sessions in a row of losses. Oslo Børs Benchmark Index_GI fell 1.14% to €1,189.72, after two sequential sessions in a row of losses, on what was an all-around negative trend exchanging session today.
Earnings Per Share
As for profitability, AIRTHINGS has a trailing twelve months EPS of kr-0.62.
More news about AIRTHINGS.
7. GENSIGHT BIOLOGICS (SIGHT.PA)
-8.29% Price Change
GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. The company also develops products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. GenSight Biologics S.A. was incorporated in 2012 and is headquartered in Paris, France.
CAC 40 ended the session with GENSIGHT BIOLOGICS dropping 8.29% to €0.50 on Thursday, after four sequential sessions in a row of losses. CAC 40 dropped 0.85% to €7,340.77, following the last session’s upward trend on what was a somewhat negative trend trading session today.
Earnings Per Share
As for profitability, GENSIGHT BIOLOGICS has a trailing twelve months EPS of €-0.15.
Volume
Today’s last reported volume for GENSIGHT BIOLOGICS is 469601 which is 63.59% above its average volume of 287051.
Volatility
GENSIGHT BIOLOGICS’s last week, last month’s, and last quarter’s current intraday variation average was a negative 3.91%, a negative 1.87%, and a positive 3.73%.
GENSIGHT BIOLOGICS’s highest amplitude of average volatility was 3.91% (last week), 4.37% (last month), and 3.73% (last quarter).
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, GENSIGHT BIOLOGICS’s stock is considered to be overbought (>=80).
More news about GENSIGHT BIOLOGICS.
8. TIETOEVRY (TIETO.OL)
-8.19% Price Change
TietoEVRY Oyj operates as a software and services company. It operates through six segments: Tietoevry Create, Tietoevry Banking, Tietoevry Care, Tietoevry Industry, Tietoevry Transform, and Tietoevry Connect. The Tietoevry Create segment provides digital agenda to create competitive products, as well as uses design, data, and cloud technologies for data-driven businesses. This segment also offers software and data engineering services. The Tietoevry Banking segment provides software products for digital transformation and financial institutions. The Tietoevry Care segment offers modular and interoperable software, reinventing Nordic health, and social care services. The Tietoevry Industry segment offers software and data solutions across various industries, such as public sector, pulp and paper, and utilities. The Tietoevry Transform segment provides enterprise-wide transformation across customers' business processes, applications and infrastructure. The Tietoevry Connect segment operates a cloud platform that provides a range of infrastructure choices ensuring security, resilience, and compliance for the customer's business. The company was formerly known as Tieto Oyj and changed its name to TietoEVRY Oyj in December 2019. TietoEVRY Oyj was founded in 1968 and is headquartered in Espoo, Finland.
Oslo Børs Benchmark Index_GI ended the session with TIETOEVRY dropping 8.19% to €320.80 on Thursday while Oslo Børs Benchmark Index_GI dropped 1.14% to €1,189.72.
Earnings Per Share
As for profitability, TIETOEVRY has a trailing twelve months EPS of kr19.18.
PE Ratio
TIETOEVRY has a trailing twelve months price to earnings ratio of 16.73. Meaning, the purchaser of the share is investing kr16.73 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.07%.
More news about TIETOEVRY.
9. BALYO (BALYO.PA)
-8.19% Price Change
Balyo SA designs, develops, and markets material handling robots worldwide. The company offers robotic pallet and reach trucks, tuggers, stackers, counterbalanced stackers, very narrow aisles, and autonomous mobile robots. Its products are used in intelligent pallet detection, barcode scanning, inter-building transport, push button configuration, machine interface, ERP interfacing, and palletizers; and WMS interface and 3D camera applications. The company serves 3PL, automotive, e-commerce, and consumer goods industries. Balyo SA was founded in 2004 and is headquartered in Arcueil, France.
CAC 40 ended the session with BALYO sliding 8.19% to €0.54 on Thursday while CAC 40 slid 0.85% to €7,340.77.
Earnings Per Share
As for profitability, BALYO has a trailing twelve months EPS of €-0.2.
More news about BALYO.
10. NANOBIOTIX (NANO.PA)
-7.73% Price Change
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.
CAC 40 ended the session with NANOBIOTIX sliding 7.73% to €1.67 on Thursday while CAC 40 slid 0.85% to €7,340.77.
Earnings Per Share
As for profitability, NANOBIOTIX has a trailing twelve months EPS of €-1.24.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, NANOBIOTIX’s stock is considered to be overbought (>=80).
More news about NANOBIOTIX.
Stay up to date with our winners and losers daily report
